Product Details
| Product Name:
Bemnifosbuvir |
CAS No.:
1998705-64-8 |
| Purity:
99.35% |
Supply Ability:
10g |
| Release date:
2024/11/14 |
Product Introduction
Bioactivity
| 名稱 | Bemnifosbuvir |
| 描述 | Bemnifosbuvir (AT-511), a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate, exhibits potent in vitro activity against HCV. |
| 體外活性 | Bemnifosbuvir is a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV[1].In the absence of cells, Bemnifosbuvir was stable when incubated in culture medium at 37°C for up to 24 h. AT-9010 was the predominant intracellular metabolite measured in all hepatocyte species and Huh-7 cell incubations with 10 μM Bemnifosbuvir and, except in mouse hepatocytes,far exceeded intracellular Bemnifosbuvir concentrations,demonstrating that the active TP was efficiently formed from its phosphoramidate protide in liver cells. In hepatocyte incubations, the relative levels of AT-9010 formed, and its accumulation over 24 h expressed as area under the curve or AUC0-24h; from most to least abundant, were rat>human >mouse >dog/monkey. |
| 體內活性 | Treatment with moxifloxacin every 8hr was accompanied by longer survival than in any other group.Tissue cultures 30hr after bacterial challenge showed considerably less bacterial growth in the spleens and lungs of moxifloxacin-treated animals than in the other groups, but not in their livers[2]. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 95 mg/mL (163.36 mM)
|
| 關鍵字 | guanosine | pangenotypic | Hepatitis C virus | SARS coronavirus | inhibit | HCV | Inhibitor | antiviral | AT511 | Bemnifosbuvir | AT 511 | SARS-CoV | nucleotide | phosphoramidate |
| 相關產品 | Nirmatrelvir | EIDD-1931 | Remdesivir | Ribavirin | Silymarin | Umifenovir hydrochloride | Sofosbuvir | Hydroxychloroquine | Ritonavir | Chloroquine phosphate | Artemisinin | Favipiravir |
| 相關庫 | 經典已知活性庫 | ReFRAME 相關化合物庫 | 藥物功能重定位化合物庫 | 抗病毒庫 | 抑制劑庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 | 共價抑制劑庫 | 抗感染化合物庫 | 核苷類化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2068818-75-5
$668.00 / 10mg
-
CAS:2241337-84-6
$53.00 / 1mg
-
CAS:13553-79-2
$39.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States